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Gene expression in mouse mammary tumor development<p>cDNA microarray-derived expression p ofiles f MMTV-Wnt-1 and MMTV-Neu transgenic mice reveal several hundred genes to be dif-ferentially exp essed at ach stage of breast tumor dev lopment.</p>
Abstract
Background: In human breast cancer normal mammary cells typically develop into hyperplasia,
ductal carcinoma in situ, invasive cancer, and metastasis. The changes in gene expression associated
with this stepwise progression are unclear. Mice transgenic for mouse mammary tumor virus
(MMTV)-Wnt-1 exhibit discrete steps of mammary tumorigenesis, including hyperplasia, invasive
ductal carcinoma, and distant metastasis. These mice might therefore be useful models for
discovering changes in gene expression during cancer development.
Results: We used cDNA microarrays to determine the expression profiles of five normal
mammary glands, seven hyperplastic mammary glands and 23 mammary tumors from MMTV-Wnt-
1 transgenic mice, and 12 mammary tumors from MMTV-Neu transgenic mice. Adipose tissues
were used to control for fat cells in the vicinity of the mammary glands. In these analyses, we found
that the progression of normal virgin mammary glands to hyperplastic tissues and to mammary
tumors is accompanied by differences in the expression of several hundred genes at each step.
Some of these differences appear to be unique to the effects of Wnt signaling; others seem to be
common to tumors induced by both Neu and Wnt-1 oncogenes.
Conclusion: We described gene-expression patterns associated with breast-cancer development
in mice, and identified genes that may be significant targets for oncogenic events. The expression
data developed provide a resource for illuminating the molecular mechanisms involved in breast
cancer development, especially through the identification of genes that are critical in cancer
initiation and progression.
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Gene expression arrays are being widely used to improve the
classification of human cancers and to improve our under-
standing of the molecular changes associated with carcino-
genesis [1,2]. However, their use in defining expression
patterns in tumor evolution and in correlating genotypes with
phenotypes has been limited because of the poor availability
of tissues at different stages in cancer development and
because of the great diversity of genetic backgrounds among
individuals [3-5]. Mouse models of cancer have advantages
for exploring the use of this method: a partially defined neo-
plastic genotype, relatively uniform genetic background, and
ample sources of tissue samples from different stages in
mammary tumor evolution. Some features of expression pro-
files identified in mouse mammary tumors are shared by pat-
terns seen in RNA from human tumors [6]. By comparing
expression patterns of mammary tumors in six different
transgenic mouse models, Desai and coworkers [7] have
shown that the initiating pathway determines a distinctive
expression phenotype in tumors. In addition, using proteins
as markers of cell phenotypes, we showed that initiating
oncogenes determine the developmental status of mammary
tumor cells [8].
Members of the Wnt gene family were discovered as proto-
oncogenes that are frequently activated in mammary tumors
arising in mice infected with mouse mammary tumor virus
(MMTV) [9,10]. Wnt genes encode extracellular matrix bind-
ing proteins that control many developmental processes,
including cell fate specification and stem cell renewal; they
are also involved in mammary morphogenesis and progenitor
cell renewal [11,12]. Made as secreted glycoproteins, Wnt pro-
teins exert their biologic effects by binding to at least two
membrane receptors, namely the frizzled and low-density
lipoprotein receptor related proteins. As a result of signaling
via the 'canonical' pathway, β-catenin is stabilized, translo-
cates to the nucleus, and transactivates different sets of genes
depending on the cellular context [13].
Mice expressing Wnt-1 under the control of the enhancer ele-
ments in the MMTV long terminal repeat develop extensive
hyperplasias of the mammary glands at prepubertal ages,
mammary tumors at a median age of 6 months, and some-
times pulmonary metastases ([14]; Podsypanina K, unpub-
lished observations). Tumors in these MMTV-Wnt-1
transgenic mice appear to arise from progenitor cells in the
mammary gland, because many cells in both hyperplastic and
neoplastic lesions express putative progenitor cell markers
(such as Sca-1 and keratin-6) and efflux fluorescent Hoechst
33342 dye - a property that has been associated with stem
cells in the hematopoietic system [8,15]. The resulting tumors
also contain tumor cells with myoepithelial as well as epithe-
lial markers, implying that they arise from a progenitor cell
that gives rise to both lineages [8,15]. Because at least some
human breast cancers are also thought to arise from progeni-
tor cells [16], it is important to define better the molecular
events that lead to tumor formation in this line of mice.
Here we report the expression profiles at different steps of
tumor evolution in the MMTV-Wnt-1 transgenic model, and
we compare these profiles with those in the MMTV-Neu
transgenic model. We addressed the following questions. Can
we follow progression in MMTV-Wnt-1 transgenic mice from
hyperplasia to primary tumor? Are differences apparent
between tumors induced by different transgenic oncogenes?
Can we distinguish tumors with additional genetic alterations
in MMTV-Wnt-1 transgenic mice from those without other
known genetic alterations?
Results and discussion
Mammary tumors in MMTV-Wnt-1 transgenic mice 
have an expression profile distinct from that seen in 
mammary tumors induced by MMTV-Neu
Comparison of expression profiles of tumors from several
transgenic models has led to the identification of expression
signatures for different oncogenic pathways [7]. In order to
determine whether tumors from MMTV-Wnt-1 transgenic
mice also have a distinctive expression profile, we determined
Table 1
Tissue samples
Tissue type Abbreviation Number of samples Age (weeks) Array size
Normal virgin mammary gland VMG or V 5 9 15k
Hyperplastic mammary glands from MMTV-Wnt-1 transgenic mice WntH 7 9 15k
Mammary tumors from MMTV-Wnt-1 transgenic mice WntT 33 9-56 15k (23 arrays), 
8.7k (10 arrays)
Mammary tumors from MMTV-Neu transgenic mice NeuT 12 32-60 15k
Normal fat tissue Fat 3 12 15k
Mammary tumors from MMTV-Wnt-1 transgenic/P53-/- mice WntT/p53-/- 6 9-14 8.7k
Mammary tumors from MMTV-Wnt-1 transgenic/Pten+/- mice with 
LOH at the Pten locus
WntT/Pten+/-LOH 3 12-21 8.7k
LOH, loss of heterozygosity; MMTV, mouse mammary tumor virus.Genome Biology 2005, 6:R84
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transgenic mice and, for comparison, 12 mammary tumors
from mice carrying the MMTV-Neu transgene (Tables 1 and 2
provide sample information and a list of all comparisons).
Neu (ErbB2/HER2), a proto-oncogene that is amplified in
approximately 25% of human breast cancers [17], encodes a
member of the epidermal growth factor receptor family of
receptor tyrosine kinases [18]. It activates signaling pathways
different from those activated by Wnt-1, and the two onco-
genes can collaborate in mammary tumorigenesis [19].
The expression profiles of these two sets of tumors were
clearly separated into two groups by unsupervised average
linkage hierarchical clustering analysis (Figure 1), suggesting
that the global expression patterns of these two sets of tumors
differ significantly. This finding extends previous reports of
significant divergence in histopathobiology, cellular composi-
tion, and possibly the cell types of origin between these two
groups of tumors [8,20,21].
In an effort to identify genes that are specifically dysregulated
in tumors induced by MMTV-Wnt-1, we performed a permu-
tation t-test (see Materials and methods, below, for details)
on these two groups of array data. In total, 1,296 genes were
differentially expressed between MMTV-Wnt-1-induced and
MMTV-Neu-induced tumors (P < 0.001; Table 2 and Addi-
tional data file 1). Among the 1,296 genes that we found to be
differentially expressed between Wnt-1-induced and Neu-
induced tumors, 842 genes are represented in the 8.7k chips
used in the previous report [7]. In that study, 672 genes were
found to be differentially expressed among tumors from
MMTV-Neu, MMTV-Ha-Ras, MMTV-c-Myc, MMTV-poly-
oma middle T antigen, C3(1)/simian virus 40 T/t antigen,
and Wap-simian virus 40 T/t antigen transgenic mice using
the 8.7k chips. Comparing the 842 differentially expressed
genes in the present study with the 672 genes from the earlier
study, we found that 165 genes were present in both lists
(Additional data file 1), including 91 of the 178 genes (51%)
reported as the Neu-Ras-polyoma middle T antigen cluster
[7]. Examples of these 91 genes include Rap1-GTPase acti-
vating protein 1, matrix metalloproteinase 15, and CD81
(Additional data file 1).
It should be noted that the MMTV-Wnt-1 transgenic mice had
a mixed genetic background that was mostly FVB (>75%),
whereas MMTV-Neu transgenic mice were on a pure FVB
background. Although this small variation in genetic back-
ground between these two groups of mice is unlikely to
account for the differences in expression profiles we detected,
we cannot exclude the possibility that some of the genes iden-
tified by this analysis might be due to variation in genetic
background.
A panel of 652 genes were reported to be differentially
expressed between MMTV-Neu-induced tumors and normal
virgin mammary glands in the study of Desai and coworkers
[7] using the 8.7k chips (> two-fold). In the present study
comparing 12 tumors from MMTV-Neu transgenic mice and
five nontransgenic normal virgin mammary glands using the
15k chips, 1,263 genes were differentially expressed (P <
0.001, more than three-fold; Table 2). Among these 1,263
genes, 626 genes were represented in the 8.7k arrays used by
Desai and coworkers. Of these 626 genes, 225 (35%) over-
lapped with the 652 genes reported to be differentially
expressed between MMTV-Neu-induced tumors and normal
virgin mammary glands in the study conducted by Desai and
colleagues. We consider this to be an acceptable level of
reproducibility, considering the multiple differences in the
generation of the two data sets (including differences in
Table 2
Numbers of genes that are differentially expressed
Comparisons Number of genes differentially expressed
Tissue A (number of samples) Tissue B (number of samples) Total Up Down
WntH (7) VMG (5) 584 121 463
WntT (23) WntH (7) 388* 112 276
WntT (23) NeuT (12) 1,296 624 672
NeuT (12) VMG (5) 1,263* 419 844
WntT, H-ras mutant (12) WntT, H-ras wild-type (9) 40 31 9
WntT/p53-/- WntT (10) 113 43 70
WntT/Pten+/- LOH (3) WntT (10) 115 45 70
Expression ratio is computed by dividing the average expression level of the A group by the average expression level of the B group. The numbers of 
differentially expressed genes were determined by random permutation (P < 0.001), as described in the Materials and method section. *In selected 
comparisons, to reduce potential false signals due to stromal effects, the genes that were less than three-fold different in expression were filtered 
out from the listed total number of genes. LOH, loss of heterozygosity.Genome Biology 2005, 6:R84
R84.4 Genome Biology 2005,     Volume 6, Issue 10, Article R84       Huang et al. http://genomebiology.com/2005/6/10/R84reference RNAs, array prints, age of the virgin mammary
glands, and sample size).
Genes that were more highly expressed (P < 0.001) in MMTV-
Wnt-1-induced tumors than in MMTV-Neu-induced tumors
include genes reported to be transcriptional targets of Wnt
signaling [22-26] such as cyclin D1 (2.0-fold), c-Myc (2.0-
fold), frizzled 7 (2.1-fold), and Wnt-5a (9.2-fold; Additional
data file 1). Wnt-5b, another member of the Wnt family, was
also more highly expressed (3.7-fold) in tumors from MMTV-
Wnt-1 transgenic mice than in tumors from MMTV-Neu
transgenic mice; it remains to be determined whether this
Wnt member is also a transcriptional target of Wnt signaling.
Gene expression in mammary tumors from MMTV-Wnt-1 versus MMTV-Neu transgenic miceFigur  1
Gene expression in mammary tumors from MMTV-Wnt-1 versus MMTV-Neu transgenic mice. (a) Dendrogram of 35 mammary tumors analyzed by 
average linkage hierarchical clustering analysis using 1,932 genes selected for high variability across all tumors. 15k arrays were used. The status of Ha-Ras 
on MMTV-Wnt-1-induced tumors is color coded: red, wild-type; brown, mutant; green, unknown. (b) Western blot analysis for nidogen protein 
expression on representative mammary tumors from MMTV-Wnt-1 and MMTV-Neu transgenic mice. MMTV, mouse mammary tumor virus; NeuT, 
mammary tumors from MMTV-Neu transgenic mice; WntT, mammary tumors from MMTV-Wnt-1 transgenic mice.
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nRetinoic acid signaling has been reported to synergize with
Wnt signaling to induce gene expression [27,28]. Retinoic
acid receptor and Stra6, a gene activated by the addition of
retinoids to cultured cells [29], have also been suggested to be
targets of Wnt signaling [27]. Consistent with these reports,
we found higher level of Stra6 (P < 0.001, 9.0-fold) in
MMTV-Wnt-1-induced tumors than in MMTV-Neu-induced
tumors. In addition, cellular retinol binding protein (RBP)1,
a gene related to retinoic acid signaling, was also more highly
expressed (P < 0.001, two-fold) in MMTV-Wnt-1-induced
tumors than in MMTV-Neu-induced tumors, which is con-
sistent with our recent report that RBP1 is induced by β-cat-
enin [30].
MMTV-Wnt-1-induced tumors contain both epithelial and
myoepithelial cells in approximately equal numbers, unlike
tumors induced by the MMTV-Neu transgene, which contain
only epithelial tumor cells [8,21,31]. Consistent with these
reports, we observed higher expression levels (P < 0.001) of
myoepithelial markers, including calponin 1 (12.5-fold) and
calponin 2 (2.5-fold and 4.0-fold for two separate clones), in
tumors from MMTV-Wnt-1 transgenic than in tumors from
MMTV-Neu transgenic mice (Additional data file 1). Consist-
ent with earlier reports that tumors may arise from mammary
progenitor cells in MMTV-Wnt-1 transgenic mice [8,15], we
found that RNA encoding the candidate progenitor cell mark-
ers keratin 6 (13-fold), tenascin (3.1-fold), osteoblast specific
factor 2 (2.0-fold), insulin-like growth factor binding pro-
tein 7 (2.0-fold), and nidogen 1 (1.8-fold) [8,32] were more
abundant (P < 0.001) in tumors from MMTV-Wnt-1 trans-
genic mice. Using immunoassays, we demonstrated that ker-
atin 6 and nidogen proteins are expressed at higher level in
MMTV-Wnt-1-induced tumors than in MMTV-Neu-induced
tumors (Figure 1b) [8].
Expression profiles are similar among mammary 
tumors with additional genetic alterations in MMTV-
Wnt-1 transgenic mice
The distinct patterns of genes expressed in MMTV-Wnt-1-
induced and MMTV-Neu-induced tumors described in the
preceding section suggest that initiating oncogenes strongly
influence gene expression in the tumors arising in these two
Multidimensional scaling analysis of 18 tumor samples of indicated genotypesFigure 2
Multidimensional scaling analysis of 18 tumor samples of indicated genotypes. 8.7k arrays were used. MMTV, mouse mammary tumor virus; WntT, 
mammary tumors from MMTV-Wnt-1 transgenic mice; WntT/Pten+/- loss of heterozygosity (LOH), mammary tumors from MMTV-Wnt-1 transgenic/Pten+/
- mice with Pten loss of heterozygosity; WntT/P53-/-, mammary tumors from MMTV-Wnt-1/P53-/- mice.
WntT/Pten+/-LOH
WntT/p53-/-
WntTGenome Biology 2005, 6:R84
R84.6 Genome Biology 2005,     Volume 6, Issue 10, Article R84       Huang et al. http://genomebiology.com/2005/6/10/R84models. We have observed that other genetic events acceler-
ate tumorigenesis in MMTV-Wnt-1 transgenic mice [14,33].
We next evaluated whether the events that mediate accelera-
tion are reflected in the gene expression patterns.
We recently reported that approximately 50% of mammary
tumors in MMTV-Wnt-1 transgenic mice have activating
mutations in the Ha-Ras locus [19]. Thus, we first considered
whether tumors carrying mutant Ha-Ras have an expression
profile distinct from that observed in tumors that are wild-
type at the Ha-Ras locus. We sequenced Ha-Ras cDNA to
seek mutations in 21 out of the 23 MMTV-Wnt-1-induced
tumors: 12 tumors carry Ha-Ras mutations and nine have
only Ha-Ras wild-type alleles (Figure 1a). Tumors with and
without Ha-Ras mutations did not have distinct global
expression profiles (Figure 1a). Independent multidimen-
sional scaling (MDS) and hierarchical clustering of these 21
tumors based on expression profiles also did not separate
them according to Ha-Ras status (data not shown). Neverthe-
less, permutation t test identified 40 genes differentially
expressed between tumors bearing wild-type Ha-Ras and
those carrying a mutant Ha-Ras (Table 2 and Additional data
file 2). This is more than expected (P < 0.001) but many fewer
than we saw in our earlier comparison between MMTV-Wnt-
1-induced and MMTV-Neu-induced tumors. In addition, the
average fold difference is much smaller (Additional data file
2) than that in the earlier comparison.
We previously determined that loss of either p53 or Pten
accelerates mammary tumorigenesis in MMTV-Wnt-1 trans-
genic mice [34,35]. To further investigate the influence of
these genetic alterations on expression patterns in MMTV-
Wnt-1-induced tumors, we determined the expression pro-
files of six tumors from MMTV-Wnt-1 transgenic mice that
were p53 null and three tumors from MMTV-Wnt-1 trans-
genic/Pten+/- mice that had lost the wild-type allele of Pten
(i.e. loss of heterozygosity). When genes in the 8.7k array data
set from these two groups of tumors and those from 10
tumors from MMTV-Wnt-1 transgenic mice that were other-
wise wild-type were subjected to analysis by MDS or unsuper-
vised hierarchical clustering, the three groups of samples
could not be separated from each other (Figure 2 and data not
shown). These findings suggest that the global expression
profiles of MMTV-Wnt-1 tumors carrying different additional
genetic alterations cannot be distinguished.
Permutation t test identified 113 genes that were differentially
expressed (p < 0.001) between tumors from MMTV-Wnt-1
transgenic mice and those from MMTV-Wnt-1 transgenic/
p53-/- mice (Table 2). Among the 113 genes, 43 were upregu-
lated, and 70 were downregulated in the latter set of tumors
(Additional data file 3). Examples of the upregulated genes
are cyclin D2 (3.7-fold), Myb (2.9-fold and 2.8-fold for two
separate clones), Bcl11a (1.5-fold), and Pbx3 (1.8-fold aver-
age), which promote proliferation or survival. Examples of
the downregulated genes are CD59a antigen (two-fold), a
potential p53 target [36], the Rb1 tumor suppressor gene, and
the Met proto-oncogene. Using similar analyses, we found
that 115 genes were differentially expressed (P < 0.001)
between tumors from MMTV-Wnt-1 transgenic mice and
those from MMTV-Wnt-1/Pten+/- mice with Pten loss of het-
erozygosity (Table 2). Forty-five were upregulated, and 70 of
them were downregulated in the latter set of tumors (Addi-
tional data file 4). Interestingly, among the downregulated
genes is tensin (two-fold), a cell adhesion molecule that is
related to Pten. Similar to the comparison between Ha-Ras
mutant and Ha-Ras wild-type tumors in MMTV-Wnt-1 trans-
genic mice, the number of genes differentially expressed and
the average fold difference were much smaller in the above
two comparisons than in the comparison between MMTV-
Wnt-1-induced and MMTV-Neu-induced tumors (Additional
data files 1, 3, and 4).
Collectively, these findings suggest that tumors from MMTV-
Wnt-1 transgenic mice are similar to each other in their global
expression profiles, regardless of whether the tumors have
additional genetic alterations. It is not known whether the
modest differences in RNA levels we identified among these
groups of tumors explain the accelerating effects of these
alterations on tumorigenesis in MMTV-Wnt-1 transgenic
mice. We plan to test some of these changes by expressing
cDNAs in mammary glands in Wnt-1 transgenic mice using
TVA-mediated somatic gene transfer technology [37].
Distinct changes in gene expression accompany the 
evolution from normal mammary glands to 
hyperplasias and to tumors in MMTV-Wnt-1 transgenic 
mice
Hyperplastic lesions are widespread in MMTV-Wnt-1 trans-
genic mice before the development of mammary tumors [14].
To determine whether unique gene expression patterns
accompany the evolution from normal mammary cells to
hyperplasias and then to tumors, we compared expression
profiles among mammary glands of nontransgenic virgin
mice, hyperplastic mammary glands, and mammary tumors
from MMTV-Wnt-1 transgenic mice. Unsupervised
hierarchical clustering analysis and MDS showed that expres-
sion profiles from these three groups of tissues were sepa-
rated from each other (Figure 3a and data not shown). The
difference between hyperplastic and normal glands is
unlikely to be due to decreased contribution of stromal RNA
in the preparation of RNAs from the hyperplastic glands from
MMTV-Wnt-1 transgenic mice, because the expression levels
of epithelial and myoepithelial marker genes (keratin 19, cal-
ponin 1, and calponin 2) were not significantly statistically
different between hyperplastic mammary glands from
MMTV-Wnt-1 transgenic mice and mammary glands from
age-matched nontransgenic virgins.
In total, 584 genes were differentially expressed (P < 0.001,
Table 1) between hyperplastic mammary glands from MMTV-
Wnt-1 transgenic mice and normal mammary glands fromGenome Biology 2005, 6:R84
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more highly expressed in the hyperplastic glands (Additional
data file 5), which includes some of the known transcriptional
targets of Wnt signaling such as c-Myc (3.6-fold) and frizzled
7 (2.1-fold). This list may therefore provide an important
starting point for confirming mammary-specific target genes
and for discovering novel in vivo targets of Wnt signaling. In
fact, two genes in this list, namely RBP1 (2.9-fold) and tumor-
associated calcium signal transducer (3.5-fold), were shown
to be upregulated by β-catenin in 293 cells in our recent stud-
ies [30].
One of the greatest challenges in identifying specific genes
and expression patterns associated with the evolution from
hyperplastic glands to tumors is the change in cellular compo-
sition. Normal and MMTV-Wnt-1-induced hyerplastic ductal
trees are embedded in stroma, but tumors often contain much
less stroma. Thus, the differential contribution of RNA from
the stromal cells may skew array analysis, which is based on
total RNA content. However, stromal cells are mostly large
adipocytes whose RNA to mass ratio is small; thus, the rela-
tive contribution of RNA from these cells is probably much
less than it appears to be from histologic assessment. The
average expression level of epithelial and myoepithelial
markers (keratin 19, calponin 1, and calponin 2) was 2.6-fold
higher in the tumors (which contain very few stromal cells)
than in the hyperplastic tissues, suggesting that 38% (1/2.6 =
38%) of the RNA in the hyperplastic tissues might come from
the ducts and alveoli. Thus, to eliminate genes that were not
truly differentially expressed, we filtered out any genes that
were less than three-fold different in our comparison between
tumors and hyperplastic glands in Table 2.
Based on the above calculation, approximately 62% of the
RNAs from hyerplastic mammary glands might come from
adipocyte-rich stroma. Thus, tumor samples, which have very
little contribution from adipocytes, may appear to have
downregulated the genes that are associated with adipocytes.
In order to identify these genes, we compared the expression
profiles of a set of three fat samples with those of the 35 mam-
mary tumors from MMTV-Wnt-1 and MMTV-Neu transgenic
mice. Expression of 741 genes was at least three-fold or higher
(P < 0.001) in fat than in the mammary tumors (Table 2 and
Additional data file 6). These include published fat-specific
genes (Additional data file 6), such as fat-specific gene 27,
lipoprotein lipase, CD36, carbonic anhydrases, and solute
carrier family members [7]. We note these genes in our table
comparing hyperplastic mammary glands with tumors (Addi-
tional data file 7).
In total, 1,372 genes were differentially expressed (P < 0.001)
between tumors and hyperplastic glands from MMTV-Wnt-1
transgenic mice. Among them, expression levels for 388 dif-
fered by at least three-fold (Additional data file 7). This sub-
group is likely to contain genes that are important for the
evolution of hyperplastic lesions into tumors, including genes
that are required for tumor cell proliferation and survival.
One such candidate is c-Kit, a proto-oncogene that is fre-
quently overexpressed in cancers and that encodes a receptor
that activates both Ras and Akt pathways. The expression of
c-Kit was 3.6-fold higher in tumors than in hyperplastic
lesions (Additional data file 7), although it was similarly
expressed in normal virgin glands and hyperplastic mam-
mary glands from MMTV-Wnt-1 transgenic mice. This is con-
sistent with a recent report that c-Kit is highly expressed in
the basal group of human breast tumors compared to other
groups [38]. Using immunohistochemical staining, c-Kit pro-
tein was barely detectable in normal mammary glands from
nontransgenic mice and in hyperplastic mammary glands
from MMTV-Wnt-1 transgenic mice, but was readily and
widely detected in the tumor samples from MMTV-Wnt-1
transgenic mice (Figure 3b).
Some of the genes that were differentially expressed between
mammary tumors and hyperplastic glands in MMTV-Wnt-1
transgenic mice may be needed for evolution of tumors
induced by both Wnt-1 and other oncogenes. Other genes
may be uniquely important for induction of tumors from
hyperplastic glands in MMTV-Wnt-1 transgenic mice. For
example, certain signaling pathways may need to be activated
in hyperplastic cells in MMTV-Wnt-1 transgenic mice before
a tumor will form, but they may be optional for tumorigenesis
initiated by other oncogenes. To discover genes that might be
uniquely important for tumors to develop in hyperplastic
glands in MMTV-Wnt-1 transgenic mice, we compared the
388 genes that we found to be differentially expressed
between tumors and hyperplastic glands from MMTV-Wnt-1
transgenic mice with the 1,296 genes that we found to be dif-
ferentially expressed between tumors from MMTV-Wnt-1
transgenic and MMTV-Neu transgenic mice. Fifty-six genes
corresponding to 59 cDNA clones in the former group were
shared in the latter group (Table 3), suggesting they might be
specifically involved in neoplastic progression in MMTV-
Wnt-1 transgenic mice. Among these 56 genes, 23 were more
highly expressed and 33 were expressed at lower level in
MMTV-Wnt-1-induced tumors than in either MMTV-Wnt-1-
induced hyperplasia or MMTV-Neu-induced tumors (Table
3). The upregulated genes (P < 0.001) include TNFRSF19
(3.5-fold), NGFR (3.6-fold), apolipoprotein D (4.7-fold), and
Gene expression in mammary tumor evolution in MMTV-Wnt-1 transgenic miceFigur  3 (see following page)
Gene expression in mammary tumor evolution in MMTV-Wnt-1 transgenic mice. (a) Dendrogram of 35 samples analyzed by average linkage hierarchical 
clustering analysis, using 3,359 genes selected for high variability across all samples. 15k arrays were used. (b) Immunohistochemical staining for c-Kit in 
the indicated tissue sections. A 20× objective was used. MMTV, mouse mammary tumor virus; VMG, virgin mammary glands from nontransgenic mice; 
WntT, mammary tumors from MMTV-Wnt-1 transgenic mice; WntH, hyperplastic mammary glands from MMTV-Wnt-1 transgenic mice.Genome Biology 2005, 6:R84
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nTable 3
List of genes potentially specifically involved in neoplastic progression in MMTV-Wnt-1 transgenic mice
Expression ratio
Image ID Gene name Symbol WntH/V WntT/WntH WntT/NeuT
474107 Tumor necrosis factor receptor superfamily, member 19 Tnfrsf19 2.56 3.48 6.23
406897 Retinol binding protein 1, cellular Rbp1 2.93 3.02 1.96
572428 Cell cycle cyclin D1 Mm.35804 Cyclin D1 Ccnd1 = 5.53 1.97
536306 Hormone/GF growth/diff 1 Mm.22621 Procollagen type I α1 Col1a1 = 3.04 3.27
536526 ESTs = 8.8 5.95
329780 Cadherin 3 Cdh3 = 3.74 3.96
427360 Mus musculus, clone IMAGE:3590270, mRNA, partial cds LOC192176 = 3.5 2.44
638805 Expressed sequence AI504637 = 3.3 2.27
355990 Chondroitin sulfate proteoglycan 2 Cspg2 = 3.62 5.05
574500 ESTs = 4.13 1.65
476431 Nerve growth factor receptor Ngfr = 3.61 6.34
680894 Glial cell line derived neurotrophic factor family receptor α1 Gfra1 = 4.74 4.05
482943 Odd-skipped related 1 (Drosophila) Osr1 = 4.1 3.65
695687 Calponin 2 Cnn2 = 3.49 2.54
335572 Dihydropyrimidinase-like 3 = 3.27 7.61
621246 Interferon concensus sequence binding protein Icsbp = 3.38 4.91
482170 Four jointed box 1 (Drosophila) Fjx1 = 4.13 3.78
468019 IL-17b Il17b = 4.27 5.37
373716 Tumor-associated calcium signal transducer 2 Tacstd2 = 4.16 3.69
479405 ESTs = 3.01 4.95
722262 Wingless-related MMTV integration site 5A Wnt5a = 4.44 9.23
719592 GATA binding protein 2 Gata2 = 6.06 10.54
1247541 Apolipoprotein D Apod = 4.67 3.86
331186 Caveolin, caveolae protein, 22 kDa Cav1 0.31 0.29 3.67
596968 Caveolin, caveolae protein, 22 kDa Cav1 0.3 0.31 3.05
948509 Caveolin, caveolae protein, 22 kDa Cav1 0.52 0.18 3
386555 CD36 antigen Cd36 0.21 0.06 0.08
832585 ESTs 0.21 0.06 0.21
620819 transcription elongation factor A (SII) 1 AI158848 0.24 0.07 0.25
831701 ESTs 0.2 0.09 0.25
775253 ESTs 0.16 0.07 0.22
334182 Unknown 0.24 0.06 0.21
493675 Riken cDNA 2700018N07 gene Scd1 0.18 0.1 0.21
571367 Riken cDNA 2410012F02 gene 0.24 0.11 0.27
463388 Epoxide hydrolase 2, cytoplasmic Ephx2 0.3 0.11 0.41
374030 EST 0.25 0.11 0.33
1067881 Fc receptor, IgG, low affinity III Fcgr3 0.36 0.16 0.26
474184 Expressed sequence AW554339 0.3 0.15 0.33
579349 Expressed sequence AI593221 2410127E18Rik 0.29 0.18 0.23
874232 Riken cDNA 1110025G12 gene 1110025G12Rik 0.33 0.19 0.56
891453 Expressed sequence AI315208 AI315208 = 0.2 0.16
1399595 Riken cDNA 2810422B09 gene 1810061M12Rik 0.3 0.18 0.4
737745 ESTs 0.34 0.17 0.37
876063 BCL2/adenovirus E1B 19 kDa-interacting protein 1, NIP3 Bnip3 0.38 0.27 0.62
850642 Epoxide hydrolase 2, cytoplasmic Ephx2 0.18 0.22 0.44
1248105 Expressed sequence AI595343 AI595343 0.42 0.21 0.37
330661 Mus musculus golli-interacting protein mRNA, complete cds Nif3 0.66 0.21 0.22Genome Biology 2005, 6:R84
R84.10 Genome Biology 2005,     Volume 6, Issue 10, Article R84       Huang et al. http://genomebiology.com/2005/6/10/R84Wnt5a (4.4-fold), and the downregulated genes (P < 0.001)
include BNIP3 (2.5-fold) and caveolin (2-, 3.3-, and 3.3-fold
for three separate clones). Of note, apolipoprotein D has been
reported to be upregulated in a subset of human breast can-
cers [39], and caveolin 1, a negative regulator of the Ras-p42/
p44 mitogen-activated protein kinase cascade, has been
reported to inhibit growth in human breast cancer cells [40].
Conclusion
Our analysis of different stages of tumorigenesis in mouse
models identified changes in gene expression accompanying
tumor initiation and evolution. We also extended the report
by Desai and coworkers [7] that the initiating oncogene deter-
mines the expression profiles of primary mammary tumors.
In addition, we observed that the tumors from MMTV-Wnt-1
transgenic mice are similar to each other in their global
expression profiles, regardless of whether the tumors have
additional genetic alterations. These data may be useful for
elucidation of oncogenic signaling pathways in breast cancer
initiation and evolution.
Materials and methods
cDNA microarray slides
The mouse 15k slides and 8.7k slides used in this study were
arrayed at the National Cancer Institute microarray facility.
All slides of each array type were printed in a single batch. The
8.7k slides contain the 8700 Incyte GEM1 clone set, which are
mapped to 6,877 Unigene cluster IDs, among which 2,953 are
named genes, 2,206 are expressed sequence tags, and 1,628
are Riken cDNAs. The 15k slides contain the 8700 Incyte
GEM1 clone set and the mammary 6000 clone set; a total of
1,444 clones do not map to a Unigene cluster ID, whereas the
rest of the clones map to 10,062 unique genes as defined by
Unigene cluster ID. Among the 10,062 Unigene clusters,
3,750 are named genes, 3,922 are expressed sequence taqs,
and 2,390 are Riken cDNAs.
Sample information
All nontransgenic and MMTV-Neu transgenic animals used
in this study were on the FVB background. All MMTV-Wnt-1
transgenic mice [14] were a mixture of FVB (>75%), SJL, and
C57BL/6 strains. MMTV-Neu transgenic mice [41] were pur-
chased from Jackson Laboratories (Bar Harbor, ME, USA).
This transgenic line carries a rat cDNA encoding the wild-type
Neu protein. Fat tissues were collected from intestinal fat in
virgin FVB mice. All samples were collected fresh and snap-
frozen in liquid nitrogen. RNA was extracted by Trizol (Invi-
torgen, Carlsbad, CA, USA). Reference RNA was a mixture of
ovarian RNA (Ambion, Austin, TX, USA; Cat number 7824)
and RNA extracted from tissues of liver, spleen, kidney,
thymus, pancreas, lung, and normal lactating mammary
gland of FVB mice of 6 months of age. All reference RNA used
in this study is from a single preparation.
cDNA microarray hybridization and data extraction
The cDNA probes were prepared from a total of 35-50 µg ref-
erence RNA and 50-75 µg sample RNA from normal, hyper-
plastic, or tumor tissues, as described [42,43]. The cDNA
from reference RNA was labeled with cyanine 3-dUTP, and
that from sample RNA was labeled with cyanine 5-dUTP. Flu-
1349720 Apoptosis NIP3, Bcl-2-binding protein homolog (Nip3) mRNA Bnip3 0.37 0.29 0.52
1067414 Expressed sequence AI413399 1110001E17Rik = 0.24 0.52
832584 ESTs, Weakly similar to STHM MOUSE STATHMIN [M. musculus] 0.31 0.21 0.46
876369 Amyotrophic lateral sclerosis 2 (juvenile) homolog (human) Als2 0.41 0.29 0.39
764542 ESTs, Weakly similar to GPRY_mouse probable G protein-coupled 
receptor GPR34 [M. musculus]
Gpr43 0.49 0.24 0.43
1248075 Transcription factor 1 Tcf1 0.29 0.31 0.36
949592 ESTs, Moderately similar to hypothetical protein [H. sapiens] = 0.32 0.22
1195295 Actinin α3 Actn3 = 0.29 0.43
820307 A kinase (PRKA) anchor protein (gravin) 12 Akap12 = 0.31 0.08
864409 Riken cDNA 1200013I08 gene 1200013I08Rik 0.47 0.33 0.39
947659 Riken cDNA 2310016E22 gene 2310016E22Rik = 0.33 0.37
1396547 Myosin binding protein H = 0.25 0.45
This list displays genes that are differentially expressed between mammary tumors (WntT) and hyperplastic mammary gland (WntH) from MMTV-
Wnt-1 transgenic mice, and that are also differentially expressed between WntT and mammary tumors from MMTV-Neu transgenic mice (NeuT). 
Genes are sorted according to the average ratio of WntT versus WntH. A numeric ratio is displayed if the gene expression meets the criteria 
(statistical significance and fold cutoff) described in Table 2; otherwise, it is marked as '=', indicating that there is no significant difference between the 
two sets of samples in comparison. EST, expressed sequence tag; MMTV, mouse mammary tumor virus.
Table 3 (Continued)
List of genes potentially specifically involved in neoplastic progression in MMTV-Wnt-1 transgenic miceGenome Biology 2005, 6:R84
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norescent images of hybridized microarrays were obtained by
using a GenePix 4000 scanner (Axon Instruments, Foster
City, CA, USA). Microarray images were analyzed using the
ArraySuite software [44,45] based on the Scanalytics IPlab
platform (Scanalytics, Fairfax, VA, USA). For each cDNA
probe location, fluorescence intensity ratio and its associated
measurement quality (q) were calculated. The evaluation of
measurement quality is based on spot size, signal to noise
ratio, background uniformity, and saturation pixel percent-
age [45]. The range of measurement quality is from 1.0 to 0,
with higher measurements reflecting better quality. Areas of
the array with obvious blemishes were automatically given a
low quality value.
Statistical analysis of cDNA microarray data
Normalized log test to reference ratios and their correspond-
ing quality measurements in each experiment were calculated
as described previously [45]. A gene was excluded from fur-
ther analyses (see below for description) if the average quality
measurement was under 0.5 across samples in that specific
comparison. Approximately 14,000 genes are suitable for
analyzing on the 15k chips and 8,000 genes on the 8.7k chips.
Two methods were used to visualize the expression patterns
among samples. Both used the Pearson correlation as a simi-
larity measure. In average linkage hierarchical clustering, the
distances between samples are represented on a tree called a
dendrogram. In MDS, samples with similar expression ratios
were placed closer to each other in three dimensional space.
Average linkage hierarchical clustering analysis was imple-
mented using the CLUSTER program, and the results were
displayed using TREEVIEW [46]. MDS was developed in the
MATLAB (Natick, MA, USA) environment.
A permutation t-test was used to select genes significantly dif-
ferentially expressed between any two groups [47]. Here, a
standard t-statistic was computed between two groups on the
log-transformed ratios of each gene. The group labels were
randomly permuted and the t-statistic for each gene in the
permuted data set was calculated. The process was repeated
10,000 times. A P value was reported for each gene by com-
paring the observed statistic with the permutation statistics.
To control for multiple comparisons, only genes with P values
less than 0.001 were considered differentially expressed. The
distribution of the significant differences expected by chance
and the probability of observing as many or more differen-
tially expressed genes were calculated from the permuted
data. This latter probability is the P value reported in the
Results and discussion section.
Western blot analysis and immunohistochemical 
staining
Antibodies used include rabbit IgG directed against nidogen
and c-Kit (Santa Cruz, CA, USA). Tissues were fixed in 10%
neutral formalin and processed as previously described [34]
to obtain paraffin sections of 4 µm in thickness. For immuno-
histochemistry, the sections were boiled for 15 minutes in 10
mmol/l citrate buffer of pH 6.0 (to unmask antigen epitopes).
Endogenous peroxidase activity was inactivated by 10 minute
incubation in 3% hydrogen peroxide, and subsequent steps
were performed using Vector ABC kits and the Nova-Red sub-
strate (Vector Laboratories, Burlingame, CA, USA) following
the manufacturer's recommendations.
For Western blotting, tumors were ground to powder in liquid
nitrogen and lysed in the M-PER tissue lysis solution (Pierce,
Rockford, IL, USA) with gentle shaking overnight at 4°C. Pro-
teins in resulting supernatant (25 µg protein) were denatured
using 2-mercaptoethanol, resolved on 10% polyacrylamide
mini-gels containing 10% sodium dodecyl sulfate, and trans-
ferred to nitrocellulose membranes. The membranes were
then incubated with primary antibodies and peroxidase-con-
jugated secondary antibodies (Jackson Laboratories) in tris-
borate buffer (1 mmol/l Tris and 13.7 mmol/l NaCl, pH 7.6)/
0.05% Tween 20/5% nonfat dried milk. Proteins recognized
by specific antibodies were visualized using a chemilumines-
cent substrate (Supersignal; Pierce).
Accession number
The GEO accession number for the series of array data-sets is
GSE2860.
Additional data files
The following additional data are available with the online
version of this article: a table listing genes differentially
expressed between mammary tumors from MMTV-Wnt-1
and MMTV-Neu transgenic mice (Additional data file 1); a
table listing genes differentially expressed between Ha-Ras
mutant and Ha-Ras wild-type tumors in MMTV-Wnt-1 mice
(Additional data file 2); a table listing genes differentially
expressed between MMTV-Wnt-1-induced tumors in p53-
null and in p53-wild-type background (Additional data file 3);
a table listing genes differentially expressed between tumors
from MMTV-Wnt-1 transgenic/Pten+/- mice with loss of het-
erozygosity at the Pten locus and tumors from Wnt-1 trans-
genic/Pten+/+ mice (Additional data file 4); a table listing
genes differentially expressed between virgin mammary
glands from nontransgenic mice and hyperplastic mammary
glands from MMTV-Wnt-1 transgenic mice (Additional data
file 5); a table listing genes expressed three-fold or higher in
fat tissues than in mammary tumors from MMMTV-Wnt-1
and MMTV-Neu transgenic mice (Additional data file 6); and
a table listing genes differentially expressed between mam-
mary tumors and hyperplastic mammary glands from
MMTV-Wnt-1 transgenic mice (Additional data file 7).
Additional File 1 table listing genes differentially expressed between mammary tumors from MMTV-Wnt-1 and MMTV-Neu transgenic miceClick here for file2 H -Ras mutant and Ha-Ra wild-type tumors in MMTV-W t-1 i3  MMTV-Wnt-1-induced tumors in p53-null nd in p53-wild-typ  background4 tu ors f om MMTV-Wnt-1 t an genic/Pte +/- mice with oss of he erozygosity at the Pte  locus and tumors fro  Wnt-1 ran genic/Pten+/+ m ce5 vi in mam-ary gla s fr m ontra sg nic ice and hyper las i a arygl nds f o  TV- nt 1 transge ic mic6 expre s d thr e-fold or hi her i  fat t s uesh  in ma a y tumo s from MTV-W t-1 and Neu r sge ic ice7hyp rplas ic mamma y gla s fr m MMTV-Wnt-1 
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